Kevin Denny, MSc, MBA, DABT

Kevin Denny, a board-certified toxicologist, joined WuXi AppTec Testing in 2021 and brings extensive regulatory and nonclinical toxicology experience managing multiple IND-enabling programs from clinical development to NDA submission. A talented Study Director and Nonclinical Project Team Lead, he has a successful track record of planning, designing, and implementing drug development strategies through all regulatory submissions, including IND, CTA, NDA, MAA, BLA, and responses to CRLs. Mr. Denny has managed and developed new GLP laboratories in the United States and France. With proven capabilities in collaborating and managing nonclinical development across departments, outside investigators, and contract research organizations (CROs), he has moved projects into and through clinical development with successful approvals. Mr. Denny, a Diplomate of the American Board of Toxicology (DABT), holds master’s degrees in Regulatory Affairs, Quality Assurance, and Toxicology, as well as an MBA. He has authored or co-authored multiple approved NDAs, BLA approvals, and IND submissions. He is currently focusing on CNS, neurodegenerative disease, stroke, and traumatic brain injury.